Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (12200)	9/28/2005 11:26:49 AM
From: Galirayo	Respond to of 23958

[SGMO] It looks like it has found support here. stockcharts.com[w,a]dacayiay[db][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

To: PuddleGlum who wrote (12200)	9/28/2005 5:33:57 PM
From: Galirayo	Respond to of 23958

It seems to be a time for Bio Failures. They are Tanking AH. MarketWatch Market Pulse: Forest, Cypress: Milnacipran fails to meet statistical sig Wednesday September 28, 5:12 pm ET By Gabriel Madway SAN FRANCISCO (MarketWatch) -- Forest Laboratories Inc. and Cypress Bioscience Inc. after Wednesday's closing bell said that a Phase III study of milnacipran as a treatment for fibromyalgia did not achieve statistical significance, but the companies plan to continue its development. The companies said further analyses must be completed to confirm the development plans. Milnacipran is a norepinephrine serotonin reuptake inhibitor that has been approved for the treatment of non-pain indications in 32 countries. Fibromyalgia is a condition characterized by widespread pain and stiffness throughout the body.